TWiV 998: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the White House COVID adviser calling on doctors to combat a vacuum of medical information, adeno-associated virus type 2 in US children with acute severe hepatitis, genomic investigations of unexplained acute hepatitis in children, surveillance of SARS-CoV-2 at the Huanan seafood market, vaccine effectiveness against hospitalization among adolescent and pediatric SARS-CoV-2 cases between May 2021 and January 2022 in Canada, effectiveness of BNT162b2 after extending the primary series dosing interval in children and adolescents aged 5–17, prevalence and characteristics associated with post–COVID-19 condition among non-hospitalized adolescents and young adults, within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals, live-attenuated vaccine sCPD9 elicits superior mucosal and systemic immunity to SARS-CoV-2 variants in hamsters, Fc-γR-dependent antibody effector functions are required for vaccine-mediated protection against antigen-shifted variants of SARS-CoV-2, COVID-19 convalescent plasma utilization in the United States, FDA authorizes Gohibic (vilobelimab) injection for the treatment of COVID-19, anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO), anti-C5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19, triple combination therapy with two antivirals and monoclonal antibodies for persistent or relapsed SARS-CoV-2 infection in immunocompromised patients, and the breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of long COVID symptoms.

Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email

Become a patron of TWiV!

Links for this episode

• White House COVID adviser calls on doctors to combat medical information (STAT)
• Adeno-associated virus type 2 in US children with acute severe hepatitis (Nature)
• Genomic investigations of unexplained acute hepatitis in children (Nature)
• Surveillance of SARS-CoV-2 at the Huanan Seafood Market (ChinaXiv)
• Vaccine effectiveness against hospitalization among pediatric SARS-CoV-2 cases (PLOS)
• Effectiveness of BNT162b2 after extending the series dosing interval in children (Nature)
• Prevalence and characteristics associated with post–COVID-19 condition (JAMA)
• Within-host genetic diversity of SARS-CoV-2 lineages in unvaccinated and vaccinated individuals (Nature)
• Replication-competent-attenuated vaccine sCPD9 elicits immunity to SARS-CoV-2 variants (Nature)
• Fc-γR antibody functions needed for SARS-CoV-2 variant protection via vaccination (Nature)
• COVID-19 convalescent plasma utilization in the United States (CID)
• FDA authorizes Gohibic injection for the treatment of COVID-19  (FDA)
• IFX-1 antibody vs. supportive care for severe COVID-19 patients (Lancet)
• Vilobelimab therapy for COVID-19 critically ill patients on mechanical ventilation (Lancet)
• Triple combo therapy for relapsed SARS-CoV-2 in immunocompromised patients with antivirals and antibodies (CID)
• Neutralizing antibody response breadth to SARS-CoV-2 tied to Long COVID presence (medRxiv)
• Neurological Long COVID pathogenesis and potential therapies (Journal Cells)
• Contribute to our ASTMH fundraiser at PWB
• Dr. Griffin’s treatment guide (pdf)
• Letters read on TWiV 998
• Don’t crush Paxlovid (pdf)
• Timestamps by Jolene. Thanks!

Intro music is by Ronald Jenkees

Send your questions for Dr. Griffin to daniel@microbe.tv